Skip to main content

Table 1 Demographic and clinical characteristics of patients with neuropathy and FGFR3 antibodies

From: Clinical features with anti fibroblast growth factor receptor 3 (FGFR3) antibody-related polyneuropathy: a retrospective study

Demographics Age (years) 51.9 years (IQR 48–57)
Female gender 9 (64.3%)
Duration of symptoms (years) 1.95 (IQR 0.75–2.0)
Onset Acute (≤ 4 weeks) 3 (21.4%)
Subacute (4–12 weeks) 3 (21.4%)
Chronic (≥12 weeks) 8 (57.1%)
Initial clinical manifestations Painful paresthesia 14 (100%)
Gait instability 6 (42.9%)
Autonomic symptoms 4 (28.6%)
Constitutional symptoms (weight loss, fatigue) 6 (42.9%)
Autonomic symptoms Orthostatic hypotension 2 (14.3%)
Neurogenic bladder 2 (14.3%)
Sensory exam findings Distal sensory loss to pin prick in hands only 3 (21.4%)
Distal sensory loss to pin prick in feet only 8 (57.1%)
Distal sensory loss to pin prick in hands and feet 3 (21.4%)
Impaired vibration sensation in distal extremities 11 (78.6%)
Impaired proprioception in distal extremities 5 (35.7%)
Reflexes Reduced or absent lower limb DTRs 8 (57.1%)
Reduced or absent upper limb DTRs 2 (14.3%)
Reduced or absent upper and lower limb DTRs 1 (7.1%)
Motor exam findings Distal upper-extremity weakness (mild) 1 (7.1%)
Distal lower-extremity weakness (mild) 6 (42.9%)
No motor weakness 7 (50.0%)
Co-existing conditions Trigeminal neuralgia 3 (21.4%)
Diabetes mellitus type 1 1 (7.1%)
Grave’s disease 1 (7.1%)
Rheumatoid arthritis 1 (7.1%)
Renal cell carcinoma 1 (7.1%)
  1. Data are reported as n (%) and mean (interquartile range). DTRs deep tendon reflexes